Bannerbild German Brest Group

GBG Research at ASCO Annual Meeting 2019

27.05.2019

Data of several GBG studies conducted together with other collaborative study groups will be presented at the upcoming ASCO 2019, which will take place from May 31 to June 4 in Chicago, IL.

#3075: Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.

  • Poster Session Developmental Therapeutics and Tumor Biology (Nonimmuno); Sat, Jun 01, 8:00 AM - 11:00 AM (poster)
  • First author: C. Denkert, Institut für Pathologie Philipps-Universität Marburg, Germany
  • Poster download


#1012: Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.

  • Session: Clinical Science Symposium Targeting Breast Cancer: Breaking the Code; Sat, Jun 01, 3:36 PM - 3:48 PM (oral presentation)
  • First author: IE. Krop, Dana-Farber Cancer Institute, Boston, MA


#509: Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.

  • Poster Discussion Session on Sunday, June 2, 2019, 4:30 PM - 6:00 PM (poster discussion)
  • First author: S. Loibl, GBG Neu-Isenburg, Germany
  • Poster download


#588: Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial.

  • Poster Session Breast Cancer - Local/Regional/Adjuvant; Sun, Jun 02, 8:00 AM - 11:00 AM (poster)
  • First author: B. Seliger, Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
  • Poster download


#573: Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344).

  • Poster Session Breast Cancer - Local/Regional/Adjuvant; Sun, Jun 02, 8:00 AM - 11:00 AM (poster)
  • First author: E.Pohl-Rescigno, Center for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
  • Poster download


#TPS605: NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

  • Poster Session: Breast Cancer - Local/Regional/Adjuvant; Sun, Jun 02, 8:00 AM - 11:00 AM (poster)
  • First author: IE. Krop, Dana-Farber Cancer Institute, Boston, MA
  • Poster download


#513: Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

  • Poster Discussion Session on Sunday; June 2, 2019, 4:30 PM - 6:00 PM (poster discussion)
  • First author: A. Schneeweiss, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

#510: Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.

  • Poster Discussion Session on Sunday; June 2, 2019, 8:00 AM - 11:00 AM (poster discussion)
  • First author: O. Metzger, Dana-Farber Cancer Institute, Boston, MA

#506: GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).

  • Session: Oral Abstract Session, Breast Cancer - Local/Regional/Adjuvant; Mon, Jun 03, 11:45 AM - 11:57 AM (oral presentation)
  • First author: PA. Fasching, Department of Gynecology and Obstetrics; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
  • Presentation downlaod

News

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd